Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD)

NCT04363684 is registered in ClinicalTrials.gov with Mayo Clinic as lead sponsor.

NCT NCT04363684
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04363684 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD)
Lead sponsor
Mayo Clinic
Phase
Observational
Overall status
Recruiting
Start date
March 1, 2020
Completion date
August 31, 2030
Enrollment
2,100 (estimated)
Sites
26

Conditions

As the registry lists them; a condition with its own page is linked.

amyotrophic lateral sclerosis, behavioral variant frontotemporal dementia (bvftd), c9orf72, corticobasal degeneration (cbd), frontotemporal lobar degeneration (ftld), ftd with amyotrophic lateral sclerosis (ftd/als), grn related frontotemporal dementia, mapt gene mutation, nonfluent variant primary progressive aphasia (nfvppa), oligosymptomatic progressive supranuclear palsy, oligosymptomatic psp (opsp), progressive supranuclear palsy (psp), semantic variant primary progressive aphasia (svppa), tbk1 gene mutation